FDA reviews DNA-based colon cancer screening kits

The Food and Drug Administration is weighing the benefits and risks of two experimental colon cancer screening tests which use DNA from a patient's stool to detect dangerous tumors and growths.

FDA scientists have questions about the accuracy and the real-world impact of the kits, if they are approved. The agency posted its reviews of the tests from Epigenomics and Exact Sciences online, ahead of a two-day meeting that starts Wednesday.

Doctors have long used stool tests to look for hidden blood that can be a warning sign of tumors and .

Both tests reviewed by the FDA were more accurate at detecting tumors and worrisome growths than the traditional blood stool test. However, both tests also returned more false positives—reporting growths when none were actually present.


Explore further

New test offers greater accuracy in early detection of colorectal cancer

© 2014 The Associated Press. All rights reserved.

Citation: FDA reviews DNA-based colon cancer screening kits (2014, March 24) retrieved 17 October 2019 from https://medicalxpress.com/news/2014-03-fda-dna-based-colon-cancer-screening.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more